En bref : The weight-loss drug boom entered a new phase in spring 2025. Analysts called a leadership change between the two drug giants, a Swiss device maker sold its diabetes unit to concentrate on injectors, a care provider built a business on tapering medication, and a 62-year-old dieting brand filed for bankruptcy. Read together, these moves show value migrating from the molecule itself toward delivery, adherence, and the discipline of deprescribing.
The drug race tightened at the top
For two years Novo Nordisk set the pace in obesity and diabetes. In 2025 that lead narrowed. BMO Capital Markets judged that Eli Lilly had caught up, citing Lilly’s stronger clinical and commercial portfolio as tirzepatide took share and a pipeline of next-generation candidates advanced. The market reacted sharply to the shift in sentiment.
A close contest at the top of a category this large creates room across the value chain. When two giants compete for the same patients, the suppliers, platforms, and services that improve access and outcomes gain leverage with both.
The picks-and-shovels play came into focus
Ypsomed made the clearest strategic statement. The Swiss company sold its diabetes-care division in a deal valued near $512 million and refocused the business on self-injection systems for subcutaneous drugs, GLP-1 (glucagon-like peptide-1) therapies among them. The company positioned itself to supply the delivery hardware for the entire category.
That choice captures a durable truth about gold rushes. The reliable returns often accrue to the suppliers of the essential tools. As injectable demand scales across every brand, the maker of the injector sits in the path of all of it.
Deprescribing turned into a business model
The most counterintuitive move came from care delivery. Virta Health reported reducing ongoing GLP-1 use by more than 50% among members while sustaining weight loss, which cuts cost for payers. The company built revenue on helping patients achieve results on lower medication doses over time.
Payers face a structural challenge as demand for these drugs surges, because the budget impact compounds with every new prescription. A service that preserves outcomes while trimming drug spend speaks directly to that pressure, and it points to a large market for responsible, outcomes-first care around the drug class.
The old guard felt the disruption
The clearest casualty marked the end of an era. WeightWatchers, weighed down by debt as GLP-1 drugs reshaped how people approach weight loss, filed for Chapter 11 bankruptcy to shed roughly $1.15 billion in debt and pivoted toward telehealth services. A brand that defined dieting for six decades restructured to survive the pharmacological wave.
The lesson reaches every incumbent adjacent to obesity care. The drugs reset consumer expectations, and the business models built for the prior era now face a hard choice between reinvention and decline. Distribution platforms, telehealth networks, and adherence services stand to absorb much of the demand that legacy programmes once held, a transition Novo Nordisk underscored when it routed Wegovy through telehealth partners.
Where the next decade of value sits
The signal for investors is consistent across all four moves. The molecule remains the engine, and the compounding value now gathers around it: the injector that delivers the dose, the platform that distributes it, the service that sustains the outcome, and the program that knows when to taper. Each of these wins inside the regulated, reimbursed boundary of chronic-disease care.
That reading sits at the core of how Allegory Capital evaluates the metabolic wave. The companies worth backing build the delivery, adherence, and care infrastructure that every drugmaker in the race will need, whichever brand leads at the top.
Références
- Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts: https://www.fiercepharma.com/pharma/eli-lilly-overtaking-novo-nordisk-diabetesobesity-market-analysts
- Ypsomed carves out diabetes business in $512M deal to focus on GLP-1 self-injectors: https://www.fiercebiotech.com/medtech/ypsomed-carves-out-diabetes-business-512m-deal-focus-glp-1-self-injectors
- Virta Health cuts GLP-1 use for weight loss over 50%, delivering payer cost savings: https://www.businesswire.com/news/home/20250404450508/en/Virta-Health-Cuts-GLP-1-Use-for-Weight-Loss-Over-50-While-Driving-Significant-and-Sustained-Outcomes-Delivering-Major-Cost-Savings-for-Payers
- WeightWatchers files for bankruptcy: https://www.cnn.com/2025/05/06/business/weight-watchers-bankruptcy
- Novo Nordisk expands Wegovy access via telehealth collaborations: https://www.prnewswire.com/news-releases/novo-nordisk-expands-patient-access-to-authentic-fda-approved-wegovy-via-collaborations-with-multiple-telehealth-organizations-302441147.html
